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Abstract
Background: This research describes current clinical and demographic features sampled from
reproductive endocrinology programs currently offering in vitro fertilization (IVF) in the Middle
East.
Methods: Clinic leadership provided data via questionnaire on patient demographics, demand for
IVF services, annual cycle volume, indications for IVF, number of embryos transferred, twinning
frequency, local regulations governing range of available adjunct therapies, time interval between
initial enrollment and beginning IVF as well as information about other aspects of IVF at each center.
Results: Data were received from representative IVF clinics (n = 13) in Cyprus, Egypt, Iran, Israel,
Jordan, Lebanon, Qatar, Saudi Arabia and Turkey. Mean (± SD) age of respondents was 47.8 ± 8
yrs, with average tenure at their facility of 11.2 ± 6 yrs. Estimated total number of IVF programs in
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each nation responding ranged from 1 to 91. All respondents reported individual participation in
accredited CME activity within 24 months. 76.9% performed embryo transfers personally;
blastocyst transfer was available at 84.6% of centers. PGD was offered at all sites. In this population,
male factor infertility accounted for most IVF consultations and the majority (59.1%) of female IVF
patients were < 35 yrs of age. Prevalence of smoking among female IVF patients was 7.2%. Average
number of embryos transferred was 2.4 (± 0.4) for patients at age < 35 yrs, and 2.9 (± 0.8) at age
> 41 yrs. For these age categories, twinning (any type) was observed in 22.6 (± 10.8)% and 13.7 (±
10.4)%, respectively. In 2005, the average number of IVF cycles completed at study sites was 1194
(range 363–3500) and 1266 (range 263–4000) in 2006. Frozen embryo transfers accounted for
17.2% of cycles at these centers in 2005. Average interval between initial enrollment and IVF cycle
start was 8 weeks (range 0.3–3.5 months).
Conclusion: This sampling of diverse IVF clinics in the Middle East, believed to be the first of its
kind, identified several common factors. Government registry or oversight of clinical IVF practice
was limited or nonexistent in most countries, yet number of embryos transferred was nevertheless
fairly uniform. Sophisticated reproductive health services in this region are associated with minimal
delay (often < 8 weeks) from initial presentation to IVF cycle start. Most Middle East nations do
not maintain a comprehensive IVF database, and there is no independent agency to collect
transnational data on IVF clinics. Our pilot study demonstrates that IVF programs in the Middle East
could contribute voluntarily to collaborative network efforts to share clinical data, improve quality
of care, and increase patient access to reproductive services in the region.
Background
Free exchange of medical information at departmental or
multi-institutional levels has been characterized as an
important, positive component of modern medical prac-
tice [1,2]. Such forums ideally provide opportunities for
medical staff to refine diagnostic and management strate-
gies in a collegial, educational setting [3]. In the Middle
East, international symposia and conferences can also
facilitate these professional goals, yet the current situation
there can present potential impediments to dialogue.
As has been the case in other areas of occasional turmoil,
political and religious discord in the Middle East has thus
far resisted attempts to bring a lasting reconciliation. In
the meantime, IVF physicians of the region are daily called
upon to see beyond this distraction and are expected to
solve complicated, frustrating problems for their patients.
An unusual, hopeful symbolism emerged from this back-
ground, where providers of the advanced reproductive
technologies were considered as being well-placed observ-
ers of what can happen when measured combinations of
balanced and opposing elements are carefully brought
together, at the most basic humanistic level, to yield new,
positive beginnings. It was the aim of this pilot study to
engage IVF physician leaders from throughout the Middle
East in a preliminary, voluntary international discourse
on the advanced reproductive technologies.
Methods
This research sampled data on IVF practice patterns
(national, institutional and individual) in the Middle East
using data derived from a voluntary 35-part question-
naire, developed in consultation with a multidisciplinary
team and influenced by current SART reporting guidelines
(USA). It consisted of three sections: 1) general questions
about IVF in the sample country, 2) questions about IVF
practiced at the respondent clinic, and 3) specific data on
the individual completing the questionnaire (Table 1).
The definition of "Middle East" was a modified version of
that used for current international tax calculations and air-
fare determination as established by the International Air
Transport Association (IATA). The IATA lists the following
as constituents of the "Middle East": Bahrain, Egypt, Iran,
Iraq, Israel, Jordan, Kuwait, Lebanon, Pakistan, Palestin-
ian territories, Oman, Qatar, Saudi Arabia, Somalia,
Sudan, Syria, United Arab Emirates, and Yemen. Note that
IATA nomenclature includes Pakistan, Somalia and Sudan
as Middle East nations, although for our investigation
these were omitted and Cyprus and Turkey (IATA
included neither as "Middle East") were substituted.
The US National Library of Medicine/PubMed public
search engine was used to query each country from this
roster coupled with search terms "IVF" or "embryo" to
identify clinics currently involved in published fertility
research. Abstracts retrieved with author e-mail contact(s)
were then used to communicate with each clinic. It was
anticipated that some IVF programs might choose not to
contribute formal research papers to the medical literature
(and thus be missed by Medline/PubMed search). There-
fore, general public internet search engines were also que-
ried in the same manner to locate advertisements, press
releases, downloadable IVF patient instructions, etc. orig-Journal of Experimental & Clinical Assisted Reproduction 2007, 4:3 http://www.jexpclinassistreprod.com/content/4/1/3
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inating from programs of the region. When neither
method identified at least one IVF center within a Middle
East country, the American citizen's service office at the
local US. Embassy was directly contacted to verify that our
search was complete or to confirm that IVF was not cur-
rently offered at any site within that country.
Data were received by secure email and tabulated by coun-
try of origin; summary data were reported where only one
center per country responded. Each facility was given an
opportunity to verify all information before final analysis.
No unsolicited questionnaires were tabulated for analysis;
the Wilcoxon rank-sum test was used for comparison
between groups.
Results
Completed questionnaires were received from 13 IVF pro-
grams over a period of four months representing nine
nations in the Middle East. Data were provided by two
programs in Iran, Israel, Saudi Arabia and Turkey. Basic
Table 1: Questionnaire.
Nation/state queries::
1) In your country, what is the grand total of IVF centers in operation there at present (defined as a facility currently capable of performing oocyte 
retrieval and embryo transfer)?
2) In your country, when was the very first IVF cycle actually undertaken? If that first cycle did not result in a birth, then in what year was the first IVF 
cycle that yielded a viable delivery?
3) In your country, is there a national registry of IVF data? If not, is one planned or under discussion?
4) In your country, describe the range of costs typically associated with IVF? Is this expense typically covered by insurance, governement, or other 
third-party payment?
5) In your country, is donor oocyte IVF lawfully permitted, and if yes, how much are the donors compensated (if anything)?
6) In your country, is IVF regulated or controlled by any national or other governmental agency? If yes, please describe.
7) In your country, are physicians and/or IVF clinics permitted to advertise to the public directly regarding advanced reproductive medical 
treatment?
8) In your country, is preimplantation genetic diagnosis legally permitted?
9) In the next five (5) years, do you anticipate the number of IVF centers in your country will increase, decrease, or remain essentially unchanged?
Queries specific to your institute::
1) When did your facility open (treat first patient for IVF)?
2) At your center, what percentage of your IVF patients are under age 35 at time of their IVF cycle?
3) At your center, what percentage of your IVF patients are age 35–37 at time of their IVF cycle?
4) At your center, what percentage of your IVF patients are age 38–40 at time of their IVF cycle?
5) At your center, what percentage of your IVF patients are over age 41 at time of their IVF cycle?
6) At your center, what is the average number of embryos transferred for each of the 4 age categories above?
7) At your center, what was the total number of IVF patients who had an embryo transfer in 2006? In 2005?
8) Has your center ever performed a blastocyst transfer?
9) At your center, what is the average rate of twin pregnacy (either monozygotic or dizygotic) for each of the 4 age categories above?
10) At your center, what percentage of your IVF patients undergo thawed embryo transfer (FET)?
11) At your center, what percentage of your IVF patients are donor-egg recipients?
12) At your center, what is the most common indication for IVF? What percentage of your IVF cycles are done exclusively for male factor 
infertility?
13) At your center, what percentage of your IVF patients are smokers (this question concerns female patients only, not partners)?
14) What is the approximate cost (in local currency) for basic IVF (without ICSI, PGD etc) at your center?
15) At your center, what is the approximate interval of time between when an (uncomplicated) IVF patient first registers and when her IVF 
programme actually starts?
16) At your center, for patients who successfully conceive after IVF, at what gestational age are they usually released from your clinic to return to 
their OB provider?
17) Does your facility operate any branch or satellite offices to facilitate cycle monitoring for IVF patients? If yes, how many?
Questions for the person answering this inquiry::
1) What is your current position with your IVF clinic (lab director, physician, etc)?
2) How long have you worked at your current IVF programme?
3) When was the approximate date (and location) of the last accredited meeting/conference you attended?
4) What is your present age?
5) Have you ever presented your research at an accredited meeting/conference (either oral or poster)?
6) Do you have any academic affiliation? If yes, please describe.
7) Do you personally perform embryo transfers?
8) Do you personally accept appointments for IVF patients (either new or returning)?
9) Do you personally attend patients at births, perform Cesarean deliveries, or otherwise provide obstetric services to patients?Journal of Experimental & Clinical Assisted Reproduction 2007, 4:3 http://www.jexpclinassistreprod.com/content/4/1/3
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demographic information on the region stratified by
responding and non-responding countries is summarized
in Table 2.
Mean (± SD) age of respondents was 47.8 ± 8 yrs. On aver-
age, these individuals reported being at their respective
clinics for 11.2 ± 6 yrs. All study participants reported par-
ticipation in accredited CME meetings within the previous
24 months, and 100% had presented formal research
reports before such bodies. Conference sites attended by
staff included Aqaba (Jordan), Barcelona (Spain), Cairo
(Egypt), Durban (South Africa), Lyon (France), New Orle-
ans (USA), Valencia (Spain), and Yazd (Iran). Most (10/
13) personally performed embryo transfer, and 11 of 13
(84.6%) were actively involved in new or returning IVF
patient consultation. While all programs offered prenatal
referrals outside their clinic by the end of the first trimes-
ter, 8 of 13 (61.5%) providers indicated they were
involved in obstetrical care for their pregnant IVF patients
by "attending them at delivery". None of the sampled IVF
programs identified any local ordinances or regulations
prohibiting advertisement of advanced reproductive med-
ical services directly to the public; as expected, estimated
total number of IVF programs generally varied with popu-
lation (range 1–91, data not shown).
In this population, most couples presenting for IVF
included women < 35 yrs of age (59%), and 8.7% of such
female IVF patients were age > 41 (see Table 3). Delivery,
clinical pregnancy, or miscarriage rates were not tabulated
by institution for this study. We found PGD to be legally
available in all sampled countries of the Middle East, and
extended in vitro culture permitting blastocyst transfer
was reported by 84.6 % (11 of 13) centers (data not
shown). Anonymous donor oocyte IVF was offered in
Cyprus, Iran, Israel and Lebanon, but only under specified
circumstances in the latter three countries. Elsewhere in
the Middle East this service was not available. Patient cost
for IVF was, on average, under US$2500 and sometimes
free (Table 3). Because no contact information was avail-
able from any source regarding IVF centers in Bahrain,
Iraq, Kuwait, Oman, Palestinian territories, Syria, UAE or
Yemen, no data could be obtained from these countries.
Discussion
An area rich in history and tradition, the Middle East is
also a land of contemporary economic and political strug-
gle. Indeed, the longstanding geopolitical challenges of
the region make stability and safety highly prized–for
those outside the region and local residents as well.
Against this backdrop of complex and sometimes conflict-
ing interests is a population of > 300 million, where the
deeply personal experience of childlessness or miscarriage
must still be confronted. When viewed from beyond the
Middle East, the individual patient journey with infertility
risks being obscured by public headlines of regional
unrest. This research sought to focus attention on the
advanced reproductive technologies here, with emphasis
Table 2: Comparison of demographic features among nations where sample IVF data were collected (a) and non-sampled nations (b).
Country Population (in millions) Growth rate (%) Birth rate (per 1,000) TFR1 Life expectancy2
MF
Cyprus a 0.79 0.5 12.6 1.8 75.6 80.5
Egypt a 80.3 1.7 22.5 2.8 69.0 74.2
Iran a 65.4 0.7 16.6 1.7 69.1 72.1
Israel a 6.4 1.2 17.7 2.4 77.4 81.9
Jordan a 6.1 2.4 20.7 2.6 76.0 81.2
Lebanon a 3.9 1.2 18.0 1.9 70.7 75.8
Qatar a 0.9 2.4 15.6 2.8 71.6 76.8
Saudi Arabia a 27.6* 2.1 29.1 3.9 73.9 78.0
Turkey a 71.2 1.0 16.4 1.9 70.4 75.5
subtotal 262.6
Bahrain b 0.7 1.4 17.5 2.6 72.2 77.3
Iraq b 27.5 2.6 31.4 4.1 68.0 70.1
Kuwait b 2.5 3.6 22.0 2.9 76.3 78.5
Oman b 3.2 3.2 35.8 5.7 71.4 76.0
Syria b 19.3 2.2 27.2 3.3 69.3 72.0
UAE b 4.4 4.0 16.1 2.4 73.2 78.4
Yemen b 22.2 3.5 42.7 6.5 60.6 64.5
subtotal 79.8
p (a vs. b)3 < 0.01 0.09 0.03 0.47 0.30
Notes: 1TFR=total fertility rate (children born/woman) 2at birth, reported in years 3by Wilcoxon rank-sum test *includes 5.6 million non-nationals
source: CIA World Factbook (June 2007)Journal of Experimental & Clinical Assisted Reproduction 2007, 4:3 http://www.jexpclinassistreprod.com/content/4/1/3
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on establishing collaborative exchange among clinics and
practitioners who have made it a priority to assure the
service remains available.
Although previous multinational reports on IVF practice
have made important contributions to our field [4-6],
none have focused specifically on the Middle East. It is an
admittedly difficult arena in which to conduct interna-
tional research, yet the current study finds IVF experts
throughout the Middle East willing to share data and work
collaboratively. Wherever contacts could be made, institu-
tions throughout the region unconditionally accepted the
invitation to participate in this voluntary study.
Recognizing differences across political, religious, or cul-
tural spectrums, our investigation identified common
findings not previously noted in a multinational Middle
Eastern sample. For example, a relatively high proportion
of male factor indications for IVF (with attendant need for
ICSI) noted in smaller Middle Eastern groups [7], and the
current study; supports extension of this earlier finding to
a broader population of the region.
Additionally, compared to Western practitioners, Middle
East IVF physicians more often offer seamless care for
patients conceiving after IVF with many personally attend-
ing their patients at delivery. This is in sharp contrast to
USA practice, where the doctor performing embryo trans-
fer is very rarely the same practitioner dividing the umbil-
ical cord at delivery. Differences in patient comfort and
satisfaction between the "unified" vs. "fragmented" pro-
vider approach have not been specifically studied from
the perspective of the medical consumer, but form the
basis of further research.
Another characteristic among sampled clinics was the
presence of government subsidies for qualified infertility
treatment. In many of the countries studied here, national
health policy has tended to favor public support of costly
IVF programs [8], in contrast to the general experience in
USA where public mandates and private insurance cover-
age for IVF are uncommon [9,10]. Our data were also con-
sistent with those reported previously [11], in that even
where expense associated with IVF was not subsidized,
average direct cost to IVF patients in these countries
remained markedly lower than the cost of comparable
treatment in USA. Furthermore, this study found that
despite limited or non-existent formal government regula-
tion of clinical IVF practice in the region, the number of
embryos transferred remained nevertheless fairly uniform
among the sampled institutions (Table 3).
Rapid advancements in the assisted reproductive technol-
ogies have frequently brought IVF providers to the fore-
front of bioethical and religious dialogues concerning
which therapies can or should be offered. Muslim beliefs
historically have included a proscription against third-
party donation in infertility, and IVF is usually regarded as
permissible with the proviso that it does not involve use
of donor gametes or surrogacy [11-13]. Likewise Judaism
allows use of assisted reproduction treatments as long as
the oocyte and sperm originate from the couple them-
selves [14-16]. The clinics sampled here appear to have
successfully adapted their mode of practice, conforming
Table 3: Summary of patient and treatment characteristics from representative IVF centers (n = 13) in the Middle East.
Age (yrs)
< 35 35–37 38–40 > 41
Patient distribution % 59.1 (15.6) 17.9 (6.5) 14.1 (9.9) 8.7 (7.2)
Twinning frequencya % 22.6 (10.8) 18.1 (8) 13.7 (10.5) 13.7 (10.4)
FET % 17.3
Smokingb %7 . 2
#ET 2.4 (0.4) 2.7 (0.6) 2.8 (0.6) 2.9 (0.9)
Enroll-to-treat intervalc Weeks 7.5
OB referral timed Weeks 8
% Male factor 50.3
Direct patient cost/cyclee 2500 (range 0–4059)
Notes: Data reported as mean (± SD), except as noted FET=frozen embryo transfers (all ages) ET=total embryo transfers
amonozygous + dizygous
breported tobacco use among female patients only (all ages)
caverage time from first appointment to gonadotropin start for IVF (all ages)
dgestational age when patient discharged from IVF clinic to obstetrician for prenatal care (includes programs who discharge patients on the day 
following ET and those who offer prenatal care in continuity with IVF treatment
emean patient cost/IVF cycle in USD (some programs provide first 2 IVF cycles free to qualified residents)Journal of Experimental & Clinical Assisted Reproduction 2007, 4:3 http://www.jexpclinassistreprod.com/content/4/1/3
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to these expectations. Indeed, there was no projected
decline in the number of local IVF centers in this geo-
graphical region, indicating a population comfortable
with present practice standards/outcomes and where
demand for the advanced reproductive technologies is
likely to grow.
Several limitations of this investigation must be acknowl-
edged. Sampling only one or two clinics per country may
not represent an accurate national cross-section of all IVF
activity. It was impossible to locate and establish contact
with all IVF programs in the Middle East, however. The
total number of extant IVF clinics in each nation was
essentially an estimate provided by helpful practitioners
who may not have access to current, comprehensive statis-
tics. A meaningful "response rate" to our questionnaire
therefore could not be calculated. While demographic
comparison between the sampled and non-sampled
countries found few important differences, measures of
population growth rate and total fertility were signifi-
cantly higher among non-sampled nations. It may be that
this finding reflects reduced local demand for IVF clinical
services, and may partially explain the difficulty in retriev-
ing data on IVF from these sites.
Descriptive research of this type also invites reporting
bias. Since it is possible that some IVF programs in the
Middle East received our questionnaire but declined to
respond after reviewing its content, we may have uninten-
tionally selected IVF centers that were better organized or
with superior statistics. A solution to such ascertainment
bias may emerge as governmental agencies gather this
type of data more effectively and include a mandate to
make it available to the general public. The difficulty in
establishing contacts with some IVF facilities in the region
implies efforts to improve communication via internet
would be helpful, not just for inter-clinic cooperation but
also to facilitate patient education and better awareness of
services.
Conclusion
It has never been more critical for IVF providers to be
mindful of cultural and religious perspectives on the
advanced reproductive technologies, as such social factors
often work actively to shape public opinion on compli-
cated bioethical matters. Since clinical outcomes may be
compared only if treatment is carried out under equiva-
lent circumstances and complete standardized data are
collected, building bridges to share information freely
across international borders is crucial. It has been shown
that appropriately designed registries contribute to effec-
tive assessment in reproductive health technology [17],
and this pilot study provides an encouraging framework
to achieve this goal in the Middle East.
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